Research demonstrated that Stachydrine significantly reduced the migration and invasion capabilities of HepG2 liver cancer cells by suppressing the activation of TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. The gene discussed is AKT1; the disease is liver cancer.